GOLD
Ascend Advanced Therapies
Ascend Advanced Therapies (Ascend) is gene to GMP specialist adeno-associated virus (AAV) contract, development, and manufacturing organization (CDMO) built on decades of expertise and industry veteran teams previously sitting within therapeutics companies.
With science and service at the core of our business, our current capabilities span early-stage discovery work, feasibility studies, process development, regulatory support, and drug-substance GMP manufacturing up to 200L. All of which are enabled by an extensive analytical portfolio with >50 in-house characterization and release assays, leading analytical development expertise and GMP QC capabilities in Europe and US.
Our state-of-the-art GMP manufacturing facility out of Florida (USA) is currently producing late-stage clinical AAV material and holds available GMP capacity in late 2025. This site is equally undergoing capacity expansion in parallel to support commercial scale manufacturing and bring online a fully automated fill/finish line and 500L bioreactor capabilities.
We have a high-quality HEK293 AAV manufacturing platform that has been scaled-up to 200L and accommodates both conventional triple-transfection or use of our proprietary EpyQâ„¢ AAV production system with two-plasmid technology. EpyQ has previously been used in 3x clinical programs and has shown benefits in both yields and quality through improved transfection efficiency and reduced levels of packaged impurities.
Let’s build the future of gene therapy together.